MM-111 clinical trials
Also written MM-111.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses MM-111 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MM-111
- 2
Studies by the year they started
4 studies that test it; most in 2009 (1)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses MM-111 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and StomachTerminatedPhase 2Merrimack PharmaceuticalsNCT01774851Written as MM-111How we know
- A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive CancerCompletedPhase 1Merrimack PharmaceuticalsNCT01304784Written as Cisplatin, Capecitabine, Trastuzumab and MM-111How we know
- A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive CancersCompletedPhase 1Merrimack PharmaceuticalsNCT00911898Written as MM-111How we know
- MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast CancerCompletedPhase 1Merrimack PharmaceuticalsNCT01097460Written as MM-111 + HerceptinHow we know
Codes
What other systems call MM-111 · ClinicalTrials.gg INT006086
- MeSH (NLM) C573311MM-111One source NLM
- UNII (FDA) 6IJ4CQY76OMM-111Confirmed FDA, NLM
- NCI Thesaurus C85486Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C573311 | MM-111 | One source NLM |
| UNII (FDA) | 6IJ4CQY76O | MM-111 | Confirmed FDA, NLM |
| NCI Thesaurus | C85486 | Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.